Bevacizumab, an anti–vascular endothelial growth factor treatment for which 1 biosimilar has been approved to date, has been shown to improve quality of life for patients with glioblastoma—and to delay disease progression—but has not prolonged patients’ overall survival. However, recent research suggests that using 4 older drugs together with bevacizumab could provide a more effective treatment protocol.
Bevacizumab, an anti—vascular endothelial growth factor (anti-VEGF) treatment for which 1 biosimilar has been approved to date, has been shown to improve quality of life for patients with glioblastoma—and to delay disease progression—but has not prolonged patients’ overall survival.
However, recent research suggests that using 4 older drugs together with bevacizumab could provide a more effective treatment protocol. Writing in Medical Sciences, Richard E. Kast, MD, describes the current research supporting this regimen.
The drugs in question are apremilast, which treats psoriasis; dapsone, an antibiotic that treats Hansen disease; zonisamide, which treats seizures; and telmisartan, which treats hypertension.
Using these drugs in combination with bevacizumab is expected to lower intracranial pressure, allow for steroid-sparing treatment, enhance bevacizumab’s effects, provide synergy with temozolomide, exert anti-glioma effects, and have low risk of adverse events.
All of these drugs, writes Kast, are low-risk drugs when they are used individually, and are all relatively inexpensive and widely available. Phase 3 testing of the regimen will be necessary prior to general use, however.
Reference
Kast RE. Paths for improving bevacizumab available in 2018: the ADZT regimen for better glioblastoma treatment. Med Sci. 2018;6(4); 84. doi:10.3390/medsci6040084.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.